Employers › Amylyx Pharmaceuticals
Recordkeeping fees per participant · Amylyx Pharmaceuticals Retirement Plan · plan year 2024
$40.02
Higher than 32% of the 14,075 plans $10 to 50M that report it.
= $10,645 / 266
Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251011050314NAL0014084496001, received 2025-10-11
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251011050314NAL0014084496001, received 2025-10-11
Percentiles compare this plan with the Schedule H plans $10 to 50M in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-10-11.
Administrative expenses excluding investment management, per participant
$40.02
Higher than 22% of the 24,371 plans $10 to 50M that report it.
= $10,645 / 266
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251011050314NAL0014084496001, received 2025-10-11
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251011050314NAL0014084496001, received 2025-10-11
Administrative expenses per participant
$50.32
Higher than 16% of the 25,098 plans $10 to 50M that report it.
= $13,385 / 266
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251011050314NAL0014084496001, received 2025-10-11
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251011050314NAL0014084496001, received 2025-10-11
Administrative expenses as a share of assets
0.071%
Higher than 17% of the 25,132 plans $10 to 50M that report it.
= $13,385 / $18,759,978
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251011050314NAL0014084496001, received 2025-10-11
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251011050314NAL0014084496001, received 2025-10-11
Employer contributions per participant
$8,315
Higher than 98% of the 24,050 plans $10 to 50M that report it.
= $2,211,801 / 266
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251011050314NAL0014084496001, received 2025-10-11
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251011050314NAL0014084496001, received 2025-10-11
Employer share of total contributions
34.7%
Higher than 74% of the 24,084 plans $10 to 50M that report it.
= $2,211,801 / $6,373,248
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251011050314NAL0014084496001, received 2025-10-11
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251011050314NAL0014084496001, received 2025-10-11
Plan terms are described in Amylyx Pharmaceuticals, Inc.'s SEC filings: Form 10-K filed 2026-03-03. No term could be quoted from them with the required precision.
2E profit-sharing · 2F ERISA 404(c) plan · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2S pre-approved plan document · 2T default investment (QDIA) · 3D IRS pre-approved plan · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20251011050314NAL0014084496001, received 2025-10-11
| Field | Value | Source |
|---|---|---|
| Plan sponsor | AMYLYX PHARMACEUTICALS INC. | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Plan name | AMYLYX PHARMACEUTICALS RETIREMENT PLAN | Form 5500, line 1a; PLAN_NAME pos 16; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Sponsor EIN / plan number | 46-4600503 / 001 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Sponsor location | CAMBRIDGE, MA | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Industry (business code) | 325410, Manufacturing | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Filing received | 2025-10-11 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Amended filing | no | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Participants, beginning of year | 352 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Active participants | 121 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Participants, end of year | 269 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Participants with an account balance | 266 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Total assets, beginning of year | $18,502,622 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Total assets, end of year | $18,759,978 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Net assets, end of year | $18,759,978 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Total income | $9,223,741 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Net income | $257,356 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Employer contributions | $2,211,801 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Participant contributions | $4,055,887 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Other contributions (incl. rollovers) | $105,560 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Total contributions | $6,373,248 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Benefit payments | $8,913,121 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Total expenses (incl. benefit payments) | $8,966,385 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Total administrative expenses | $13,385 | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Recordkeeping fees | $10,645 | Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Investment advisory and management fees | $2,740 | Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Administrative expenses excluding investment management | $10,645 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Held in common/collective trusts | $113,595 | Schedule H, line 1c(9) col (b); INT_COMMON_TR_EOY_AMT pos 51; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Held in mutual funds | $18,466,642 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20251011050314NAL0014084496001, received 2025-10-11 |
| Independent auditor | CBIZ CPAS P.C. | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20251011050314NAL0014084496001, received 2025-10-11 |
Position = column in the DOL layout for form year 2024. Filing 20251011050314NAL0014084496001, received 2025-10-11.
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| ADP, INC.recordkeeper | RECORD KEEPER | 37 Participant loan processing; 50 Direct payment from the plan; 15 Recordkeeping and information management; 64 Recordkeeping fees; 26 Investment advisory (participants); 49 Other services; 99 Other fees | $13,385 | yes |
| ADP BROKER-DEALERrecordkeeper | RECORD KEEPER | 60 Sub-transfer agency fees; 59 Shareholder servicing fees | $0 | yes |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20251011050314NAL0014084496001, received 2025-10-11.
| Figure | 2023 | 2024 | Change |
|---|---|---|---|
| Total assets | $18,502,622 | $18,759,978 | 1.4% |
| Participants with a balance | 348 | 266 | -23.6% |
| Administrative expenses | $2,563 | $13,385 | 422.2% |
| Recordkeeping fees per participant | $6.75 | $40.02 | 492.6% |
| Employer contributions | $2,068,444 | $2,211,801 | 6.9% |
Prior filing 20241015180111NAL0017006771001, received 2024-10-15; the plan years are contiguous.
Sponsor name as filed: AMYLYX PHARMACEUTICALS INC.; SEC registrant: Amylyx Pharmaceuticals, Inc. (CIK 1658551, matched by EIN; display name from the Form 10-K cover).